Evidence map›Paper›PMID 40241367›Full record

ArticleZhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics2025

[Mechanism of 2,6-DMBQ attenuates airway inflammatory responses in asthmatic mice via the mTOR signaling pathway].

Juan Li, Shu-Fang Li, Xiao-Man Xiong, Qiu-Yan Yang, Xue-Li Xie, Yan-Li Zhang

Abstract readEnglish Abstract
In one paragraph

Article in Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Juan LiDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Shu-Fang LiDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Xiao-Man XiongDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Qiu-Yan YangDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Xue-Li XieDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Yan-Li ZhangDepartment of Pediatrics, Third Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesTo investigate the therapeutic effects and mechanisms of 2,6-dimethoxy-1,4-benzoquinone (2,6-DMBQ) in a mouse model of asthma.

methodsSPF-grade BALB/c mice were randomly divided into 7 groups (

resultsCompared with the normal control group, the OVA group showed increased enhanced pause values, inflammation scores from hematoxylin-eosin staining, positive area from periodic acid-Schiff staining, percentage of eosinophils, IL-17/IL-10 ratio, serum immunoglobulin E levels, and relative expression levels of p-AKT/AKT and p-p70S6K/p70S6K (

conclusions2,6-DMBQ can inhibit the mTOR pathway to alleviate airway inflammation in asthmatic mice, possibly by mitigating the imbalance between Th17 and regulatory T cells.

Indexed as

AsthmaBenzoquinonesSignal TransductionTOR Serine-Threonine KinasesAnimalsBronchoalveolar Lavage FluidFemaleImmunoglobulin EInterleukin-10Interleukin-17LungMiceMice, Inbred BALB CBenzoquinonesImmunoglobulin EInterleukin-10Interleukin-17mTOR protein, mouseTOR Serine-Threonine Kinases2,6-Dimethoxy-1,4-benzoquinoneBronchial asthmaMammalian target of rapamycin pathwayMouseTh17/Treg imbalance

Identifiers

PMID40241367
PMCPMC12010994

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.